Executive Board

Executive Board 2016-2018

President

Wolgang Wick, Heidelberg, Germany

Wolfgang Wick is Chairman of the Neurology Clinic at the University Hospital Heidelberg and Director for Neurooncology at the National Tumor Center at the University of Heidelberg, Germany.

He is currently conducting multicenter phase I-III randomized trials for the Neurooncology Working Group (NOA) of the German Cancer Society, the European Organisation for Research and Treatment of Cancer (EORTC), the EU GAPVAC consortium, as well as a number of multicenter trials with the pharmaceutical industry. He is a steering committee member of the NOA and the European Association for Neuro-Oncology (EANO), as well as chairman of the EORTC Brain Tumor Group.

His main scientific interests include resistance mechanisms, immunotherapy, biomarkers, and radiosensitization. Professor Wick has written more than 250 publications in peer-reviewed journals, such as the Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Nature, Nature Medicine, Neurology, Neuro Oncology, Annals of Neurology, The New England Journal of Medicine and Journal of Clinical Investigation.

Wolgang Wick, Heidelberg, Germany
Past President

Michael Weller, Zurich, Switzerland

Dr. Michael Weller has been Chairman of the Department of Neurology at the University Hospital Zurich, Switzerland, since 2008. He qualified in medicine in Cologne, Germany, after completing his thesis on proliferative disorders of the retina. A postdoctoral fellowship at the Department of Clinical Immunology, University Hospital Zurich, Switzerland, followed where he identified death receptor targeting as a potential treatment strategy for malignant gliomas. In 2005, he was appointed Chairman of the Department of General Neurology at the University Hospital Tübingen, Germany, where he had previously received his education in clinical neurology.

Dr. Weller has received several awards in recognition of his important contributions to cancer research, including the German Cancer Award in 2007. He served as the Chairman of the Neuro-Oncology Group of the German Cancer Society from 2001-2008. He is the Chairman of the German Glioma Network of the German Cancer Council, joined the Executive Board of the European Association for Neuro-Oncology (EANO) in 2010 and was elected President of EANO in 2014.

Dr. Weller was involved in major practice-changing clinical trials including the registration trial for temozolomide in glioblastoma and served as PI on the NOA-03, NOA-04, NOA-08 and G-PCNSL-SG-1 trials in Germany and the DIRECTOR and ARTE trials in Switzerland. He is also a member of the editorial boards of the Journal of Neurochemistry, Journal of Neuro-Oncology, Brain and Glia, and he was the Associate Editor Europe of Neuro-Oncology from 2006-2013.

Dr. Weller has co-authored more than 550 original publications in peer-reviewed journals, including The New England Journal of Medicine, Science, Nature, Nature Medicine, Lancet Oncology, Proceedings of the National Academy of Sciences of the United States of America, The Journal of Clinical Investigation, and The Journal of Clinical Oncology.

Michael Weller, Zurich, Switzerland
Treasurer

Geoffrey Pilkington, Ryde, United Kingdom

Pilkington is Professor of Cellular and Molecular Neuro-oncology, and Head of the Brain Tumour Research Centre, University of Portsmouth [Previously, Professor of Experimental Neuro-oncology, Kings College, London]

He is Immediate Past President of the British Neuro-oncology Society, Executive Board Member and Treasurer of European Association of Neuro-Oncology and Founder and Co-ordinator of the South of England Brain Tumour Alliance. Geoff was formerly Programme Secretary, British Neuropathological Society and Committee Member. Geoff was also a Founder Member of EANO and BNOS.

Geoff was member of various national and international Advisory Boards of grant awarding bodies (e.g. CwCUK, Norwegian Research Council), reviewer for over 40 grant awarding bodies throughout the world, Editorial Board member of 5 international journals and reviewer for over 55 scientific journals. Examiner of over 30 PhD students (UK and overseas) and Supervisor of over 30 PhD students (London and Portsmouth)

Geoff is author of numerous publications on brain tumour biology, in particular development of in vitro and in vivo models of glioma, as well as investigations on the underlying mechanisms of brain tumour invasion. Currently he is involved with drug repurposing for glioblastoma and screening of delivery vehicles through a 3D all human model of the blood brain barrier.

Geoff has spent his entire career (Forty three years) in brain tumour research, having started work on chemical neuro-carcinogenesis where he studied brain cancer stem cells and brain tumour development at the Middlesex Hospital Medical School in the early 1970s and subsequently spent 23 years at the Institute of Psychiatry, King’s College, London, latterly as Professor of Experimental Neuro-oncology. In 2003 he moved to the School of Pharmacy & Biomedical Sciences, University of Portsmouth, as Professor of Cellular & Molecular Neuro-oncology & Director of Research.

Over the years the research focus of his group has been development of models for the study of intrinsic brain tumours, elucidation of the mechanisms underlying diffuse local invasive behaviour in glioma and development of novel strategies for mitochondrial mediation of apoptosis in glioma. Over the years Geoff has published numerous papers on the results of his research on human glioma and has developed various “all human” three-dimensional in vitro models to study brain tumour invasion and the blood-brain barrier.

Geoffrey Pilkington, Ryde, United Kingdom
EANO Executive Board Member

Elizabeth Cohen-Jonathan Moyal, Toulouse, France

Elizabeth Cohen-Jonathan Moyal is professor or Radiation Oncology, Head of the Radiation Oncology department at the Comprehensive Cancer Center Institut Universitaire du Cancer, Toulouse, France and is specialized in translational research in radiotherapy, and more particularly in brain tumours. She is also the head of the radiobiology team in the Toulouse Research Cancer Center (CRCT) and works on the involvement of biologic factors controlling the micro-environment, the radioresistance and hypoxia.

Based on the results obtained in her lab, she designs and develops in her radiation oncology department clinical trials in glioblastoma as well as in lung cancer associating targeted drugs directed against the targets that have been validated in vitro and in vivo in orthotopic models in her lab. The clinical trials that she develops are associated with biomarkers studies and metabolic and functional imaging to better understand the radiosensitizing effects of these targeted drugs.

Her involvement in translational research in radiotherapy, led her to create and organize the international meeting “Novel targeting drugs and radiotherapy: from the bench to the clinic” which is now the radio-chemotherapy meeting of the European Society of Radiation Oncology (ESTRO).

Elizabeth Cohen-Jonathan Moyal, Toulouse, France
EANO Executive Board Member

Roger Henriksson, Stockholm, Sweden

Professor and chief Physician Roger Henriksson, MD, PhD, is since January 2012 the head of the newly established Regional Cancer Center Stockholm Gotland. The cancer center, after decision of the Swedish government and in full agreement by the Swedish parliament, of six regional cancer centres in Sweden has the aim to build up a new national and regional organisation for cancer care and clinical cancer research. In this position he is also a member of the national board for collaboration between the six regional cancer centres. He came to this position from being the head and the Physicianin-chief at the Department of Oncology and Radiotherapy (Radiumhemmet), Karolinska university hospital, Stockholm.

He is also a co-director of the StratCan network in cancer research at the Karolinska Institutet. Henriksson is the chairman of the Swedish Society of Oncology. He was appointed on his chair as Professor of experimental Oncology 1995 and as a senior consultant 1995 at the Department of Radiation Sciences & Oncology, Norrlands University Hospital, Umeå, Sweden. He has been head and deputy head of this department 1994 – 2003, Managing Director of the Cancer Research Unit 1987 -2008, acting head of the division of Neuro-Oncology, lung cancer and malignant melanoma 1995 -2008.

Professor Henriksson is medical/scientific advisor for The National Board of Health & Welfare and The National Dental and Pharmaceutical Benefits Agency (TLV), and has served as external advisor for EMA. He has also previously been on a position part time for 7 years as Medical Advisor AstraZeneca Oncology Europe.

Professor Henriksson has published more than 300 original full papers in peer reviewed journals, including articles in Nature, New Engl J Med, JCO and the Lancet. He is also the author of numerous oncology chapters in professional medical textbooks.

His main research is within the field of clinical and experimental oncology with a focus on brain tumours. He has got several awards from different research organisations and patient advocacy groups. Henriksson has also actively taking part in the establishment of patient advocacy groups in lung cancer and brain tumours.

Roger Henriksson, Stockholm, Sweden
EANO Executive Board Member

Colin Watts, Cambridge, United Kingdom

Dr Watts’ research group aims to improve the treatment and survival of patients with Glioblastoma (GB) by understanding the molecular genetic heterogeneity of individual tumours and using that data to develop a novel molecular stratification of GB suitable for application in clinical trial design.

Dr Watts qualified from the University of Newcastle upon Tyne and trained in neurosurgery in Cambridge and London where he completed his specialist training in 2004. His research training was supported by the MRC first as a Clinical Fellow, gaining his doctorate from the University of Cambridge in 1999, and subsequently as a Clinician Scientist. In 2010 he was awarded a HEFCE Clinical Senior Lecturer position at the University of Cambridge.

As a practicing neurosurgeon Dr Watts has established a dedicated neurosurgical-oncology research clinic, which is closely integrated with his lab. His group has established protocols for the efficient derivation of tumour-initiating stem-like cells from fresh GBM samples and utilized them to develop patient-specific xenogeneic models. He has adapted fluorescent surgery to develop Fluorescence-Guided Multiple Sampling (FGMS), which allows spatially discrete tissue samples to be taken from individual patients. This is providing novel insights into the impact of surgical sampling bias on our understanding of the complex genomic landscape of GBM, its clonal architecture and phylogeny at the level of the individual patient.

His clinical research seeks to couple fluorescence-guided cytoreduction with locally delivered therapies. He is chief investigator in the GALA-5 trial, which aims to identify clinical benefit from combining fluorescence with intra-operative chemotherapy.

Dr Watts’ clinical practice specialises in surgical neurooncology, with a particular interest in intrinsic gliomas and cerebral metastases.

Colin Watts, Cambridge, United Kingdom
EANO Executive Board Member President-Elect

Martin van den Bent, Rotterdam, Netherlands

After completing my training as a neurologist I joined in 1992 the Neuro-Oncology Unit of Erasmus MC - Daniel den Hoed Cancer Center in Rotterdam, the Netherlands. This neuro-oncology unit is focused on the treatment of primary brain tumors and on neurological complications of cancer and its treatment. We  integrated in 2013 this unit with the brain tumor specialists of the department of neurosurgery into a Brain Tumor Center at Erasmus MC Cancer Center. I believe in the multidisciplinary approach, and in good clinical evidence as the corner stone of treatment. For those reasons I have been the principle investigator many large international multicenter phase II and III trials on both high and low grade glial tumors. Most of these have been conducted through the EORTC Brain Tumor Group, as this important network allows the conduct of glioma trials that make a difference. I have served between 2003 and 2009 as the chair of this internationally well recognized group, and I am currently member of the EORTC Board. I have had the honor of receiving in 2004 and in 2014 the award for excellence in clinical research by the Society for Neuro-Oncology, and to be the 2015 recipient of the 2015 ECCO Clinical Research Award. Bringing the latest research and clinical developments to patients is important, and for that reason I have established and co-chaired four editions of a bi-annual EORTC-EANO-ESMO educational course on brain tumors. We have several European professional organizations that at least partially focus on brain tumors, these need to collaborate but more importantly: EANO is pre-eminently the multidisciplinary organization for brain tumors and therefore the leading European organization for physicians and scientists devoted to neuro-oncology Recently a European Rare Cancer Network has been proposed, of which I coordinated the glioma part. A key role for EANO is obviously needed here as well.

Martin van den Bent, Rotterdam, Netherlands
EANO Executive Board Member

Roberta Rudà, Turin, Italy

Dr. Roberta Rudà is a Neurologist who has been involved in neuro-oncology for up to 20 years.

Since 2011 she is Head of the Outpatient Service and Multidisciplinary Brain Tumor Board, City of Health and Science Hospital/University of Turin. She is also the Coordinator of the Neuro-Oncology Network of the  Regione Piemonte and Valle D’Aosta.

Dr. Roberta Rudà is Professor of Neuro-Oncology in the Residency Programs of Neurosurgery and Diagnostic Imaging/Radiotherapy of the University of Turin.

The major research areas are represented by primary brain tumors with particular interest in lower grade gliomas, epilepsy, and primary CNS lymphomas. Translational research, functional neuroimaging and neurological complications of cancers (in particular neoplastic meningitis and brain metastases) have been a focus of interest as well. In this regard Dr. Rudà is Principal Investigator in several international clinical trials.

Dr. Rudà is Member of the Editorial Board of Neuro-Oncology, Neuro-Oncology Practice, Journal of Neurosurgical Sciences and World Federation of Neuro-Oncology Magazine, and Reviewer for J. Neuro-Oncology, Lancet Oncology, J. Neurology and Epilepsia.

Dr. Rudà has been a Member of the Scientific Committee of EANO since 2014, and Member of the EANO Task Forces for Guidelines in PCNSL, Ependymomas, Leptomeningeal Metastases, Brain Metastases and Palliative/Supportive Care. She is Member of the RANO Groups on Leptomeningeal Metastases and Epilepsy in Brain Tumors, and of the Brain Tumor Group of EORTC.

She is Secretary of the Italian Association of Neuro-Oncology (AINO) since 2013 and she has been the chair of the Local Organizing Committee of the EANO Congress in Turin, 2014.

Roberta Rudà, Turin, Italy
Nurse EANO Executive Board Member

Ingela Oberg, Cambridge, United Kingdom

I thought I’d take this opportunity to introduce myself as the new EANO lead nurse and extend my heartfelt thanks to Hanneke Zwinkels for all her help in getting me settled into my role.

Although I am Swedish, I live and work in Cambridge UK and have done so since I qualified as nurse in Stockholm, Sweden back in 1997. Having always had an affinity to neuro, I started my career working within the neuro critical care unit at Addenbrooke’s Hospital, Cambridge and have been in my current role as senior neuro -oncology specialist nurse since 2009.

On a personal note, I am a mother of two sprightly and very energetic twin boys (Oskar and Freddie) who are just 18 months old and help keep me young at heart. I have personal experiences of losing a close family member to an Anaplastic Oligodendroglioma, so I am also an ardent advocate on patient and carer issues.

Raising the nursing profiles and importance of neuro oncology nursing both nationally within the UK and now within EANO is something I am very passionate about and proud to be involved in, and I hope to be able to carry on and build upon the great success that Hanneke instilled in the Nursing forums. I would love to hear your thoughts and any contributions you may wish to see in future.

I look forward to working closely with you all and also look forward to welcoming you to the next nursing conference in Heidelberg.

Ingela Oberg, Cambridge, United Kingdom
EANO Executive Board Member

Guido Reifenberger, Düsseldorf, Germany

Guido Reifenberger is Professor of Neuropathology and since 2000 head of the Department of Neuropathology at Heinrich Heine University Düsseldorf, Germany. He studied medicine in Düsseldorf and was lateron trained in Neuropathology at the University Hospital Düsseldorf and the Sahlgrenska Hospital in Gothenburg, Sweden. From 1997 to 2000 he worked as associate professor of molecular neurooncology at the University of Bonn, Germany.

Prof. Reifenberger co‐chairs the Brain Tumour Reference Centre of the German Society of Neuropathology and Neuroanatomy (DGNN) and is the vice speaker of the German Neurooncology Working Group (NOA). At Heinrich Heine University Düsseldorf he also serves as speaker of the interdisciplinary Centre for Biological and Medical Research (BMFZ) and the iBrain Graduate School for Translational Neuroscience.

For more than 20 years now, the major scientific interest of Prof. Reifenberger’s research group has been the elucidation of molecular genetic alterations driving the development and malignant progression of primary brain tumours, in particular gliomas. A special research focus is placed on the translation of novel molecular findings into the clinic by establishing and clinically validating new diagnostic, prognostic and predictive molecular markers. Moreover, his group applies cutting‐edge high‐throughput molecular profiling technologies as novel tools not only for gene discovery but also for improved molecular diagnostics of brain tumours. Other topics of ongoing research projects include the role of altered expression of microRNAs in glioma pathogenesis as well as the investigation of molecular pathomechanisms leading to glioma resistance to alkylating agent chemotherapy.

Guido Reifenberger, Düsseldorf, Germany
EANO Executive Board Member

Matthias Preusser, Vienna, Austria

Matthias Preusser is an Associate Professor of Medicine and a consultant in Medical Oncology at the Medical University of Vienna. He serves as Coordinator of the CNS Tumours Unit at the Comprehensive Cancer Centre Vienna, and his research focuses on biomarkers and therapy in brain tumours. Recent works focus on the characterization of inflammatory infiltrates and immune checkpoint molecules in various types of brain tumours, the biology of brain metastases and identification of novel treatment options for meningiomas. Dr. Preusser is a Steering Committee member of the European Organisation for Research and Treatment of Cancer Brain Tumour Group and is leading or actively involved in several international clinical trials in Neuro-oncology.

Matthias Preusser, Vienna, Austria
Co-opted EANO Executive Board Member

Jérôme Honnorat, Lyon, France

Jérôme Honnorat is Professor of Neurology at the University Claude Bernard Lyon 1, Chair of the Department of Neuro-Oncology at Hospices Civils de Lyon, Team leader of the “Synaptopathies and Autoantibodies” team (SynatAc), at the Institute NeuroMyoGene (UMR INSERM U1217, CNRS 5310, UCBL1), and coordinator of the French reference center on paraneoplastic neurological syndromes and autoimmune encephalitis. He was past-president of the ANOCEF (French neuro-oncological society) 2002-2008.

His main scientific interests include gliomas treatment, immunotherapy, biomarkers, paraneoplastic neurological syndromes and autoimmune encephalitis. He has published over 330 PubMed referenced papers on topics primarily related to autoimmune encephalitis, paraneoplastic neurological syndromes and neuro-oncology.

Jérôme Honnorat will be the EANO 2019 Meeting President

Jérôme Honnorat, Lyon, France